Literature DB >> 26714935

Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer's disease.

Vincenzo De Luca1, Maria Donata Orfei2, Sara Gaudenzi2, Carlo Caltagirone2, Gianfranco Spalletta2.   

Abstract

In Alzheimer's disease patients (AD), the age at onset (AAO) ranges from 40 to 90. Usually, AD patients who develop symptoms before the age of 65 are classified as early onset (EO). The best known genetic risk factor for AD is the ε4 allele of the apolipoprotein E (APOE). In this study, 474 subjects with AD were consecutively recruited in the memory clinic of the Santa Lucia Foundation in Rome. The best fitting model  for the discrimination between EO and late onset (LO) was chosen based on lowest value of the Bayesian Information Criterion, which suggests the theoretical model with minimal deviation from the empirical distribution function of AAO in our sample. The FMM was used to compare EO and LO groups with respect to the following demographic and clinical variables: gender, age, education, MMSE and NPI. Furthermore a quantitative assessment of ADL and IADL was performed. Finally, the frequency of the APOE ε4 allele was compared in EO and LO groups. Using the admixture analysis, we established that the AAO discriminating EO from LO-AD was 63-64. Higher education was associated with earlier onset in the EO but not in LO, and duration of illness was associated with earlier onset only in LO. The ε4 allele was associated with later onset in EO but earlier onset in LO. Finally, increased impairment in ADL, IADL and NPI was associated with later onset only in the LO subgroup. Thus, the ε4 allele of the APOE gene was significantly associated with both EO and LO distributions but with opposite effect, suggesting genetic heterogeneity. Additional studies are needed to further clarify the genetic mechanisms differentiating EO- and LO-AD.

Entities:  

Keywords:  APOE; Admixture analysis; Age at onset; Alzheimer’s disease; ε4 allele

Mesh:

Substances:

Year:  2015        PMID: 26714935     DOI: 10.1007/s00406-015-0663-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  31 in total

1.  The effect of job loss on overweight and drinking.

Authors:  Partha Deb; William T Gallo; Padmaja Ayyagari; Jason M Fletcher; Jody L Sindelar
Journal:  J Health Econ       Date:  2011-01-14       Impact factor: 3.883

2.  Age at onset in Canadian schizophrenia patients: admixture analysis.

Authors:  Fabio Panariello; Lauren O'Driscoll; Renan P de Souza; Arun Tiwari; Mirko Manchia; James Kennedy; Vincenzo De Luca
Journal:  Schizophr Res       Date:  2009-11-17       Impact factor: 4.939

3.  APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians.

Authors:  Oye Gureje; Adesola Ogunniyi; Olusegun Baiyewu; Brandon Price; Frederick W Unverzagt; Rebecca M Evans; Valerie Smith-Gamble; Kathleen A Lane; Sujuan Gao; Kathleen S Hall; Hugh C Hendrie; Jill R Murrell
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

Review 4.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 5.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

Review 6.  Epidemiology of Alzheimer disease.

Authors:  Christiane Reitz; Carol Brayne; Richard Mayeux
Journal:  Nat Rev Neurol       Date:  2011-02-08       Impact factor: 42.937

7.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  Comparison of behavioral and psychological symptoms in early-onset and late-onset Alzheimer's disease.

Authors:  Yasutaka Toyota; Manabu Ikeda; Shunichiro Shinagawa; Teruhisa Matsumoto; Naomi Matsumoto; Kazuhiko Hokoishi; Ryuji Fukuhara; Tomohisa Ishikawa; Takaaki Mori; Hiroyoshi Adachi; Kenjiro Komori; Hirotaka Tanabe
Journal:  Int J Geriatr Psychiatry       Date:  2007-09       Impact factor: 3.485

9.  Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer's disease.

Authors:  Yvonne Davidson; Linda Gibbons; Antonia Pritchard; Jayne Hardicre; Joanne Wren; Cheryl Stopford; Camille Julien; Jennifer Thompson; Antony Payton; Stuart M Pickering-Brown; Neil Pendleton; Michael A Horan; Alistair Burns; Nitin Purandare; Corinne L Lendon; David Neary; Julie S Snowden; David M A Mann
Journal:  Dement Geriatr Cogn Disord       Date:  2006-11-14       Impact factor: 2.959

10.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.

Authors:  R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

View more
  4 in total

Review 1.  Early-Onset Alzheimer Disease.

Authors:  Mario F Mendez
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

Review 2.  Early-onset Alzheimer Disease and Its Variants.

Authors:  Mario F Mendez
Journal:  Continuum (Minneap Minn)       Date:  2019-02

3.  A Twin Study of Sex Differences in Genetic Risk for All Dementia, Alzheimer's Disease (AD), and Non-AD Dementia.

Authors:  Christopher R Beam; Cody Kaneshiro; Jung Yun Jang; Chandra A Reynolds; Nancy L Pedersen; Margaret Gatz
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 4.  A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders.

Authors:  Sagrario Manzano; Luis Agüera; Miquel Aguilar; Javier Olazarán
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.